Enzalutamide (MDV3100) supplier|cas 915087-33-1 |DC Chemicals|Supplier|Price|Buy  

Enzalutamide (MDV3100) supplier|cas 915087-33-1 |DC Chemicals|Supplier|Price|Buy

DC Chemicals Supply: Enzalutamide (MDV3100) supplier,cas 915087-33-1, Cat No. DC5069, In stock

Contact: website:www.dcchemicals.com,

sales@dcchemicals.com,order@dcchemicals.com,info@dcchemicals.com,

Tel: +86-21-61454686;Fax:+86-21-61642828；

Product name: Enzalutamide (MDV3100), Synonym:　MDV-3100;  MDV 3100. Enzalutamide, brand name: Xtandi., Cat No. DC5069, Cas: 915087-33-1, Chemical Name:N/A, Molecular Formula: C21H16F4N4O2S, MW: 464.43

Enzalutamide (MDV3100),cas 915087-33-1, Purity: >98%. Best Price and quality in the market,DC Chemicals,Primary Manufacturer, confirmed by HNMR and HPLC. MDV3100 is an androgen-receptor (AR) antagonist with IC50 of 36 nM.

MDV3100 is an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) with potential antineoplastic activity. Through a mechanism that is reported to be different from other approved AR antagonists, selective androgen receptor modulator MDV3100 inhibits the activity of prostate cancer cell ARs, which may result in a reduction in prostate cancer cell proliferation and, correspondingly, a reduction in the serum prostate specific antigen (PSA) level. AR over-expression in prostate cancer represents a key mechanism associated with prostate cancer hormone resistance. MDV3100 was discovered by Charles Sawyers who is now at Memorial Sloan–Kettering Cancer Center and Michael Jung at UCLA. MDV3100 is an experimental androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of castration-resistant prostate cancer currently in Phase 3 clinical trials. Results so far have been encouraging; Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine. Early preclinical studies also suggest that MDV3100 inhibits breast cancer cell growth.